Vanda Pharmaceuticals Inc. beat EPS estimates 0% of the time across 2 reported quarters (0 beats, 2 misses), averaging -79.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.51 | $-1.04 | -103.9% | Miss | |
| Q1 FY26 | $-0.53 | $-0.82 | -54.7% | Miss | |
| Q4 FY25 | not reported | $-0.46 | not reported | not reported | Q4 FY25 call |
Back to VNDA overview · VNDA holders · VNDA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.